regulation

ASA bans glucomannan ads over prescription pill claims

The ASA upheld four complaints on 4 November 2026 against weight loss pill adverts, ruling that glucomannan small print did not fix the overall impression

Official regulatory documents on a desk, representing an advertising watchdog ruling

The Advertising Standards Authority has upheld four complaints against online pharmacies that advertised weight loss pills, in rulings published on Wednesday 4 November 2026. Two went against Menwell Ltd, trading as Voy, whose adverts named a glucomannan food supplement in small print while the imagery showed a single white tablet. One was a video on demand advert carrying the words "Oral weight support" and "It's kind of a small deal"; the other was a poster on the side of a bus reading "The weight is over". The ASA found that consumers would read both as promoting an oral prescription only medicine for weight loss, licensed in the UK on 11 June 2026, and that the small print naming glucomannan "was not sufficient to override that impression". Two further rulings went against MedExpress Enterprises Ltd and Juniper Technologies UK Ltd over a paid Instagram story and a YouTube pre-roll. All four cited CAP Code rule 12.12.

Why the small print did not save the adverts

Both adverts' small print reproduced the glucomannan weight management claim from the Great Britain Nutrition and Health Claims Register, and the ASA did not say the glucomannan claim was itself wrong. It judged the adverts on the overall impression, including where the click took the reader, and noted landing pages that showed a tablet alongside named prescription weight loss medicines. The MHRA advised on the Voy video on demand case. Separately, the MHRA published its October 2026 advertising investigations on 4 November, listing Menwell Ltd alongside Amazon One Medical and Weightfall Ltd as companies that amended their advertising after MHRA action. MedExpress said it had already discontinued its advert; Juniper said it removed its advert in July 2026.

What this means in practice

For anyone advertising food supplements, the Voy rulings say that a compliant claim in small text does not fix an advert whose images and headline point somewhere else. The adverts were judged on what a reader would take from them as a whole, including the landing page they led to. The medicines advertising rules and the CAP Code apply across the whole of the UK, so these decisions bind advertisers in Great Britain and Northern Ireland alike. The ASA told all four companies not to promote prescription only medicines to the public in future, and said each advert must not appear again in the form complained of.

How Perqen members save

Perqen does not sell or arrange prescription medicines, and nothing here changes what we stock. Membership costs £4.99 a month or £29.99 a year and unlocks member pricing across the full catalogue.

This article reports published news and research and is for information only. Food supplements are not a substitute for a varied diet or medical care, and no product mentioned is intended to diagnose, treat, cure or prevent any disease. Speak to your GP or pharmacist before changing what you take, especially if you are pregnant, breastfeeding, or taking prescribed medicines.

Sources